search
Back to results

A Study of ASKG315 in Patients With Advanced Solid Tumors.

Primary Purpose

Advanced Solid Tumors

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
ASKG315
Sponsored by
AskGene Pharma, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Solid Tumors

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female ≥ 18 years of age.
  2. Histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available.
  3. Measurable disease, per RECIST v1.1.
  4. ECOG Performance Status of ≤ 2.
  5. Life expectancy of ≥3 months, in the opinion of the Investigator.
  6. Adequate organ function defined.
  7. Fertile patients must be willing to use effective contraceptive measures (hormonal or barrier methods or abstinence, etc.) during the trial and at least 90 days after the last dose;negative serum pregnancy test for female patients within 7 days prior to the first dose of the study drug or documentation of lack of childbearing potential.
  8. Voluntarily enrolled and signed the informed consent form, followed the experimental treatment plan and visit arrangement.

Exclusion Criteria:

  1. Received chemotherapy within 3 weeks prior to Cycle 1 Day 1; received radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, or any other anti-tumor treatments within 4 weeks prior to Cycle 1 Day 1.
  2. Received any other investigational drug for treatment that is not commercially available within 4 weeks prior to Cycle 1 Day 1.
  3. Had major organ surgery or significant trauma within 4 weeks prior to C1D1 or planning elective surgery during the study period.
  4. Received systemic glucocorticoid or other immunosuppressant treatment within 2 weeks prior to C1D1.
  5. Received immunomodulatory drugs, including but not limited to thymosin and interferon, within 2 weeks prior to C1D1.
  6. Received a live attenuated vaccine within 4 weeks prior to C1D1.
  7. Received IL-2 or IL-15 therapy within 4 weeks prior to C1D1.
  8. History of hematologic stem cell transplant or solid organ transplant.
  9. Adverse reactions to previous antitumor therapy have not recovered to CTCAE 5.0 grade ≤ 1.
  10. Cerebral parenchymal metastasis or meningeal metastasis with clinical symptoms.
  11. Serious infection requiring intravenous infusion or hospitalization, or active viral infection.
  12. Current clinically significant interstitial lung disease.
  13. History of serious cardiovascular or cerebrovascular diseases.
  14. Active or recurrent autoimmune diseases.
  15. History of Grade ≥ 3 Immune-Related Adverse Events (irAE) or Grade ≥ 2 immunotherapy-associated myocarditis associated.
  16. Other malignancies within 5 years.
  17. Bleeding symptoms of CTCAE 5.0 grade ≥3 within 4 weeks prior to C1D1.
  18. Symptomatic with uncontrolled ascites or pleural effusion.
  19. Hyperglycemia that cannot be stably controlled.
  20. History of a grade ≥ 3 allergic reaction to protein drugs.
  21. Known to have alcohol or drug dependence.
  22. Severe mental disorder or poor compliance.
  23. Pregnant or nursing women
  24. Subjects should be excluded in the opinion of investigators.

Sites / Locations

  • Harbin Medical University Cancer Hospital
  • the First Affiliated Hospital of Nanchang UniversityRecruiting
  • Shandong cancer hospitalRecruiting
  • Shanghai East HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ASKG315

Arm Description

Single or multiple ascending dose of ASKG315

Outcomes

Primary Outcome Measures

Dose limiting toxicities (DLTs)
To evaluate the safery of ASKG315 in subjects.
Adverse events(AEs)
To evaluate the safery of ASKG315 in subjects.

Secondary Outcome Measures

Maximum plasma concentration (Cmax)
To evaluate the systemic pharmacokinetics of ASKG315 in subjects.
Area under the concentration time curve (AUC)
To evaluate the systemic pharmacokinetics of ASKG315 in subjects.
Cytokine
Increase in circulating cytokine levels.
Immunocyte
Changes in immunocyte levels by flow cytometry.

Full Information

First Posted
September 19, 2022
Last Updated
February 26, 2023
Sponsor
AskGene Pharma, Inc.
Collaborators
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05554666
Brief Title
A Study of ASKG315 in Patients With Advanced Solid Tumors.
Official Title
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent in Patients With Locally Advanced or Metastatic Malignant Solid Tumors.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 15, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
October 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AskGene Pharma, Inc.
Collaborators
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study is a Phase 1, open-label, multicenter, dose escalation study to evaluate the safety, tolerability, PK and PD of ASKG315 as a single agent in patients with advanced solid tumors.
Detailed Description
Each part of the study consists of 3 periods: screening (up to 28 days), treatment and follow-up. After an initial screening period, ASKG315 will be administered once every 3 weeks by intravenous (IV) infusion. The Part 1 dose escalation consists of 6 planned escalation cohorts, with a starting dose of 3 mg.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Tumors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
56 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ASKG315
Arm Type
Experimental
Arm Description
Single or multiple ascending dose of ASKG315
Intervention Type
Biological
Intervention Name(s)
ASKG315
Intervention Description
Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
Primary Outcome Measure Information:
Title
Dose limiting toxicities (DLTs)
Description
To evaluate the safery of ASKG315 in subjects.
Time Frame
21days
Title
Adverse events(AEs)
Description
To evaluate the safery of ASKG315 in subjects.
Time Frame
21days
Secondary Outcome Measure Information:
Title
Maximum plasma concentration (Cmax)
Description
To evaluate the systemic pharmacokinetics of ASKG315 in subjects.
Time Frame
21days
Title
Area under the concentration time curve (AUC)
Description
To evaluate the systemic pharmacokinetics of ASKG315 in subjects.
Time Frame
21days
Title
Cytokine
Description
Increase in circulating cytokine levels.
Time Frame
21days
Title
Immunocyte
Description
Changes in immunocyte levels by flow cytometry.
Time Frame
21days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female ≥ 18 years of age. Histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available. Measurable disease, per RECIST v1.1. ECOG Performance Status of ≤ 2. Life expectancy of ≥3 months, in the opinion of the Investigator. Adequate organ function defined. Fertile patients must be willing to use effective contraceptive measures (hormonal or barrier methods or abstinence, etc.) during the trial and at least 90 days after the last dose;negative serum pregnancy test for female patients within 7 days prior to the first dose of the study drug or documentation of lack of childbearing potential. Voluntarily enrolled and signed the informed consent form, followed the experimental treatment plan and visit arrangement. Exclusion Criteria: Received chemotherapy within 3 weeks prior to Cycle 1 Day 1; received radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, or any other anti-tumor treatments within 4 weeks prior to Cycle 1 Day 1. Received any other investigational drug for treatment that is not commercially available within 4 weeks prior to Cycle 1 Day 1. Had major organ surgery or significant trauma within 4 weeks prior to C1D1 or planning elective surgery during the study period. Received systemic glucocorticoid or other immunosuppressant treatment within 2 weeks prior to C1D1. Received immunomodulatory drugs, including but not limited to thymosin and interferon, within 2 weeks prior to C1D1. Received a live attenuated vaccine within 4 weeks prior to C1D1. Received IL-2 or IL-15 therapy within 4 weeks prior to C1D1. History of hematologic stem cell transplant or solid organ transplant. Adverse reactions to previous antitumor therapy have not recovered to CTCAE 5.0 grade ≤ 1. Cerebral parenchymal metastasis or meningeal metastasis with clinical symptoms. Serious infection requiring intravenous infusion or hospitalization, or active viral infection. Current clinically significant interstitial lung disease. History of serious cardiovascular or cerebrovascular diseases. Active or recurrent autoimmune diseases. History of Grade ≥ 3 Immune-Related Adverse Events (irAE) or Grade ≥ 2 immunotherapy-associated myocarditis associated. Other malignancies within 5 years. Bleeding symptoms of CTCAE 5.0 grade ≥3 within 4 weeks prior to C1D1. Symptomatic with uncontrolled ascites or pleural effusion. Hyperglycemia that cannot be stably controlled. History of a grade ≥ 3 allergic reaction to protein drugs. Known to have alcohol or drug dependence. Severe mental disorder or poor compliance. Pregnant or nursing women Subjects should be excluded in the opinion of investigators.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jing Chen, MD
Phone
086-15895835292
Email
chenjing@ask-pharm.com
First Name & Middle Initial & Last Name or Official Title & Degree
Luwei Han
Phone
086- 15195873396
Email
hanluwei@ask-pharm.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jin Li, MD
Organizational Affiliation
Shanghai East Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Harbin Medical University Cancer Hospital
City
Harbin
State/Province
Heilongjiang
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yanqiao Zhang
Email
yanqiaozhanggcp@163.com
Facility Name
the First Affiliated Hospital of Nanchang University
City
Nanchang
State/Province
Jiangxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yong Li
Email
liyongcsco@qq.com
Facility Name
Shandong cancer hospital
City
Jinan
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuping Sun
Email
13370582181@163.com
First Name & Middle Initial & Last Name & Degree
Jiasheng Bian
Email
sdbjs232466@sina.com
Facility Name
Shanghai East Hospital
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jin Li, MD
Phone
086-13761222111
Email
lijin@csco.org.cn

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is no plan to make IPD or supporting information available.

Learn more about this trial

A Study of ASKG315 in Patients With Advanced Solid Tumors.

We'll reach out to this number within 24 hrs